GlassScriptPhysician profile
James Michael Williams
NPI 1760408272
$5,470.09
in general payments reported to CMS, 2019-2025
46 companies · $824 in 2025
The $824 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $732 · 2021: $724 · 2022: $788 · 2023: $756 · 2024: $1,041 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.52 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $790.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $670.11 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $493.43 | 2019-2025 | |
| Amgen INC. | $361.46 | 2019-2025 | Evenity, Prolia, Otezla |
| Sanofi-Aventis U.S. LLC | $248.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $234.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $224.93 | 2021-2024 | |
| Glaxosmithkline, LLC. | $223.25 | 2019-2024 | Shingrix, Arexvy |
| Lilly USA, LLC | $220.06 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $204.00 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $138.56 | 2019-2025 | Veozah |
| Allergan, INC. | $134.55 | 2020 | |
| Sumitomo Pharma America, INC. | $112.74 | 2023-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $103.47 | 2024-2025 | Auvelity, Symbravo |
| Antares Pharma, INC. | $102.43 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.